Eklund 1991.

Methods	Allocation: randomised. Blindness: double. Duration: 48 weeks (preceded by 15 week single blind 60mg HD/ month).
Participants	Diagnosis: schizophrenia (RDC). N=56 Age: mean ˜ 52 yrs (SD ˜ 12), range 25‐65. Sex: 37 F, 19 M. Setting: 37 community, 19 hospital.
Interventions	1. Haloperidol decanoate: dose mean 60mg/ injection (fixed dose regimen), every 4 weeks. N=18/N=20* 2. Placebo: N=23
Outcomes	Leaving the study early. Unable to use ‐ Additional medication (>30% attrition) Relapse (>30% attrition). Side effects (EPSS ‐ >30% attrition). Mental state (CPRS ‐ no SD). Physiological measures (plasma levels).
Notes	* N in HD group in abstract differs from N in paper. Authors contacted ‐ no reply.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear